Shaily Engineering Plastics is a precision plastic manufacturer generating roughly 51% of its revenue from healthcare delivery devices, specifically pen injectors for GLP-1 and insulin therapies, with the remainder split between consumer home furnishings (41%) and industrial components (8%). In Q1 FY27, healthcare revenue grew 85% year on year to INR142 crore, making it the largest segment, while consolidated EBITDA margin stood at 29.7% and PAT margin at 17.1%. The pen injector market has only a few global players, and Shaily is one of them, having supplied about 9 million delivery devices in Q1 FY27, of which 50 to 55% were for GLP-1 molecules. Its own IP-led pen platforms (Harmony, Neo, Axiom Max) and pricing above USD2 per pen, versus Chinese copycats at USD1.50 to 1.70, indicate a differentiated, high-margin niche rather than a commodity plastics business.
These economics persist because of high switching costs and regulatory barriers. A drug-device combination requires 24 to 36 months and 70 to 80% of the original program cost (INR100 to 150 crore) to switch devices, locking in customers once qualified. In Canada, 70% of the first six semaglutide filers use Shaily's device, and both approved pharma companies use it. The company has also entered semiconductor trays, where fewer than a dozen companies globally can meet dimensional tolerances and conductive plastic requirements, and consumer electronics, where no other domestic component maker meets precision requirements. These are not easily replicable capabilities; the asset base and qualification cycles take years to copy. The 29% EBITDA margin, well above the 18 to 20% typical for good manufacturing, reflects this structural advantage.
The inflection is capacity coming online. An additional 25-million-unit pen line will be operational by end-September 2026, taking total installed pen capacity to about 75 million units per annum. FY27 volume is guided at 36 million pens, and management is confident of beating it; FY28 target is 50 million. The two new lines should achieve combined output of 40 to 42 million pens at 65 to 67 parts per minute by end-FY27, and 35 to 40 million from that capacity by end-FY28. The Abu Dhabi plant, planned for 75 million pens, is targeted for commercial sales by end-FY28, with 50 to 55% of its capacity already having customer commitments or indications. By mid-2028, the business will have over 150 million units of installed pen capacity, with healthcare alone likely exceeding 70% of revenue versus 51% today, and new verticals such as semiconductor trays (revenue from Q4 FY27) and consumer electronics (USD10 million in 24 to 30 months) adding incremental streams.
Management has a track record of overdelivering on margins and revenue, even if volume guidance slipped in FY26 (actual 23.5 million pens versus an earlier 30 million guidance). Healthcare revenue jumped 139% in FY26 to INR393 crore, and EBITDA margin expanded 630 basis points to 29.0%; Q1 FY27 margin improved a further 120 basis points year on year to 29.7%. They have consistently executed on capacity additions, with the first 25-million line installed in March and the second line due by July to August, and they have signed new contracts with two additional GLP-1 customers and two global pharma pen contracts. Capital allocation is disciplined: the board approved an enabling resolution to raise up to INR500 crore annually for financial flexibility, but debt to equity was only 0.3 times as of September 2025, and cash PAT grew 62% in FY26. The company also onboarded a COO for healthcare and dedicated business development heads for Europe and North America, signaling intent to secure innovator partnerships within six quarters.
Earnings visibility is strong. Given FY27 volume of 36 million plus pens and an average selling price of over USD2, pen revenue alone could exceed USD72 million (roughly INR600 crore) assuming full year, and healthcare segment growth is already running at 85% in Q1 FY27. Gross margins are expected to improve year on year as the healthcare mix rises, and management guides to sustainable EBITDA margins in the high-20s. The key falsifier is execution on the new line efficiency: the first new line ran at 45% OEE with 8% rejections, and management targets 65 to 67 parts per minute by year-end; a failure to reach that would delay volume ramp. The other watchpoint is securing the remaining 45 to 50% of Abu Dhabi capacity commitments, and the softness in home furnishings demand (consumer segment down 24% year on year in Q1 FY27) is receding as healthcare becomes dominant. The tension between the FY26 volume miss and margin expansion is operational, not structural: line qualification delays were temporary, while the underlying demand and pricing power remain intact.
companyname: Shaily Engineering Plastics Limited ticker: SHAILY sector: Precision plastic engineering / drug delivery devices (healthcare, consumer, industrial) Shaily Engineering Plastics Limited is a precision plastic engineering company founded in 1987, headquartered near Vadodara, Gujarat. It designs, develops, tools, molds, and assembles plastic components and finished devices for customers across 35+ countries. The company operates six plants in Halol and Rania, Gujarat, with over 200 inj...
Read the full report →capex, margin expansion, regulatory approval, new product segment
FY27 pen injector capacity guided at 40-42 million units driven by new capacity ramp-up
Guidance downgradedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Shaily Engineering Plastics Limited and 4,900+ companies.
5-day free pass. No card required.